Synergistic interactions between 12-0-tetradecanoylphorbol-13-acetate (TPA) and imatinib in patients with chronic myeloid leukemia in blastic phase that is resistant to standard-dose imatinib

详细信息	查看全文 | 推荐本文 |

• 作者：Baijun Fang ; Yongping Song ; Zhengtao Han ; Xudong Wei ; Qu ; e Lin ; Xiaoxiu Zhu ; Ruyu Yang ; Junzhong Sun ; Guofeng Tian ; Xinjian Liu ; Guoshun Cao ; Yin Shi ; Neng Nie ; Dapeng Li ; Robert Chunhua Zhao
• 关键词：Chronic myelogenous leukemia ; Blastic phase ; 12-0-Tetradecanoylphorbol-13-acetate ; Imatinib ; Resistant
• 刊名：Leukemia Research
• 出版年：2007
• 期刊代码：186_01452126
• 类别：med
• 出版时间：October 2007
• 卷：31
• 期：10
• 页码：1441-1444
• 文件大小：106 K

摘要

We have demonstrated that 12-0-tetradecanoylphorbol-13-acetate (TPA) combined with vitamin D₃ (VD₃) and cytosine arabinoside (Ara C) is effective and feasible for chronic myelogenous leukemia (CML) in blastic phase (BP). In the current study, the efficacy of TPA combined with inhibitor imatinib mesylate (imatinib) was investigated in patients with CML in BP that was resistant to standard-dose imatinib (400 mg/day). The results suggested that TPA combined with imatinib (400 mg/day) might overcome disease-poor response to conventional doses. So this approach deserves further evaluation as frontline therapy for newly diagnosed CML.